Abstract
Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow.
Original language | English (US) |
---|---|
Pages (from-to) | 962-972 |
Number of pages | 11 |
Journal | JACC: Basic to Translational Science |
Volume | 4 |
Issue number | 8 |
DOIs | |
State | Published - Dec 2019 |
Externally published | Yes |
Keywords
- B-type natriuretic peptide
- cardiorenal
- heart failure
- nesiritide
- phosphodiesterase inhibition
- systolic dysfunction
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine